Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome

Integrins αvβ3 and αvβ5 regulate angiogenesis and invasiveness in cancer, potentially by modulating activation of the transforming growth factor (TGF)-β pathway. The randomized phase III CENTRIC and phase II CORE trials explored the integrin inhibitor cilengitide in patients with newly diagnosed gli...

Full description

Bibliographic Details
Main Authors: Weller, Michael, Nabors, Louis Burt, Gorlia, Thierry, Leske, Henning, Rushing, Elisabeth, Bady, Pierre, Hicking, Christine, Perry, James, Hong, Yong-Kil, Roth, Patrick, Wick, Wolfgang, Goodman, Simon L., Hegi, Monika E., Picard, Martin, Moch, Holger, Straub, Josef, Stupp, Roger
Format: Online
Language:English
Published: Impact Journals LLC 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924768/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924768/

Similar Items